This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

This study has been terminated.
(Inadequate enrollment)
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: October 6, 2008
Last updated: February 2, 2012
Last verified: February 2012
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema

Condition Intervention Phase
Diabetic Macular Edema Drug: Aliskiren Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment [ Time Frame: Baseline to week 12 ]
    The central retinal thickness was measured by Optical coherence tomography (OCT). The changes in central retinal thickness (CRT) from baseline to the end of study at week 12 were analyzed using a univariate analysis of covariance model (ANCOVA) with baseline value as a covariate and treatment as a fixed factor

Enrollment: 39
Study Start Date: September 2008
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aliskiren 300 mg
Aliskiren 300 mg once daily for 12 weeks
Drug: Aliskiren
300 mg once daily
Other Name: SPP100
Placebo Comparator: Placebo
Matching placebo once daily for 12 weeks
Drug: Placebo
Matching placebo once daily


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Type 1 or type 2 diabetes
  • Diabetic macular edema

Exclusion criteria:

  • Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)
  • Recent laser photocoagulation in the study eye
  • Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye

Other protocol-defined inclusion/exclusion criteria applied

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00768040

United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States
United States, California
Retina-Vitreous Associates
Los Angeles, California, United States
United States, Florida
National Ophthalmic Research Institute
Fort Myers, Florida, United States
United States, Georgia
Georgia Retina
Atlanta, Georgia, United States
United States, Maryland
Elman Retina Group
Baltimore, Maryland, United States
United States, Massachusetts
Joslin Clinic
Boston, Massachusetts, United States, MA
United States, Michigan
Vitreo-Retinal Associates
Grand Rapids, Michigan, United States
United States, North Carolina
Charlotte Eye, Ear, Nose and Throat Associate
Charlotte, North Carolina, United States, NC
United States, Ohio
Retina-Associates of Cleveland, Inc
Beachwood, Ohio, United States
United States, Texas
Retinal Consultants of Houston
Houston, Texas, United States, TX
Novartis Investigative Site
Arhus, Denmark
Novartis Investigative Site
Copenhagen, Denmark
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT00768040     History of Changes
Other Study ID Numbers: CSPP100A2244
EudraCT 2008-00581-23
Study First Received: October 6, 2008
Results First Received: February 2, 2012
Last Updated: February 2, 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Macular edema
Diabetic retinopathy
Diabetes mellitus type 1
Diabetes mellitus type 2

Additional relevant MeSH terms:
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on September 21, 2017